In all breast cancer patients, no distinct difference was observed in the 5-year OS and DFS rates between the Ki-67<20% and Ki-67 ≥ 20% groups (75.7% vs. 67.6%, X2 = 2.6, P = 0.11; 57.9% vs. 50.0%, X2 = 2.1, P = 0.15, respectively, Figures 6(a) and 6(b)). This evidence concerns the gene MKI67 and breast carcinoma.